Prognose
| Køb |
6 |
| Behold |
2 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Lifeward shareholders approve partnership with Oramed and potential capital injection
Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Mere på de.investing.com
Oramed receives $18 million from Scilex and announces cash dividend
Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Mere på de.investing.com
Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years
Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Mere på de.investing.com
Oramed completes repurchase of Scilex warrants for $28.5m
Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Mere på de.investing.com
Oramed buys back HTIT shares and ends joint venture
Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2026 har Oramed Pharmaceuticals allerede udloddet 0,21 € i udbytte. Den seneste udlodning fandt sted i januar.
Virksomhedstal
I det seneste kvartal havde Oramed Pharmaceuticals en omsætning på 0 € og et nettoresultat på 16,25 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | 16,25 mio. | 60,59 % |
| EBITDA | 24,99 mio. | 50,69 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 141,48 mio. € |
Antal aktier | 43,49 mio. |
Højeste/laveste i 52 uger | 4,99 € - 2,30 € |
Udbytteafkast | 6,00 % |
Udbytte TTM | 0,21 € |
Beta | 1,28 |
P/E (PE Ratio) | 1,02 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,44 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Oramed Pharmaceuticals Inc. udvikler og forsker i farmaceutiske løsninger til behandling af diabetes samt til brug af oralt indtagelige kapsler eller piller til levering af polypeptider. Virksomhedens proprietære flagskibsprodukt er ORMD-0801, en oralt indtagelig insulinkapsel, som har gennemført fase II-kliniske forsøg for behandling af personer med diabetes. Virksomheden udvikler også ORMD-0901, en oral glucagon-lignende peptid-1-kapsel, som har gennemført fase I-kliniske forsøg til behandling af type 2-diabetes, samt en vægttabsbehandling i form af en oral leptinkapsel. Virksomheden var tidligere kendt som Integrated Security Technologies, Inc. og skiftede navn til Oramed Pharmaceuticals Inc. i april 2006. Oramed Pharmaceuticals Inc. blev grundlagt i 2002 og har hjemsted i New York, New York.
| Navn | Oramed Pharmaceuticals |
| CEO | Nadav Kidron |
| Hjemsted | New York City,
ny USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 01.05.2007 |
| Medarbejdere | 13 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
Tlv | ORMP.TA |
NASDAQ | ORMP |
Frankfurt | OJU1.F |
Düsseldorf | OJU1.DU |
München | OJU1.MU |